FDA and HHS Clash Over Peptide Approvals as GLP-1 Enforcement Crackdown Intensifies

Regulatory & Political Developments

FDA and HHS Clash Over Upcoming Peptide Compounding Approvals

A major policy showdown is brewing ahead of the FDA’s Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23-24, 2026. The panel is set to weigh whether to add seven popular peptides—including BPC-157, KPV, TB-500, and MOTS-c—to the Section 503A bulks list, which would legally permit state-licensed compounding pharmacies to manufacture them.

On July 17, reports emerged that FDA officials and former Commissioner Marty Makary raised internal conflict-of-interest concerns regarding several panel members recently appointed by Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. According to The Washington Post, officials flagged that some appointees work for peptide-related businesses or clinics. Secretary Kennedy has publicly identified himself as a "big fan" of peptides and pledged to expand access, putting him at odds with FDA career scientists who recently released documents citing insufficient evidence of safety and efficacy to justify compounding these substances.

APhA Opposes Adding Peptides to 503A List

Also on July 17, the American Pharmacists Association (APhA) issued a statement urging the FDA to prioritize scientific evidence and patient safety. APhA officially backed the FDA’s recommendation not to add the nominated peptides to the 503A list, warning that the surge of unregulated online peptide markets exposes patients to contamination, inaccurate dosing, and counterfeit products.

Legal & Enforcement Actions

State and Federal Crackdowns on GLP-1s and Unapproved APIs

Enforcement actions against compounding pharmacies and suppliers handling GLP-1s and unapproved peptides have intensified this week.

• Supplier Scrutiny: The FDA recently cited U.S.-based compounding ingredient supplier Darmerica for distributing unapproved peptide ingredients that are illegal for compounding use. This follows earlier import alerts against foreign API manufacturers, such as China’s Hangzhou Yiqi Biotechnology Co. (a producer of bulk BPC-157 and TB-500), for major sterility violations.
• State Pharmacy Board Actions: State regulators are actively penalizing pharmacies that ship unapproved drugs across state lines. The Ohio Board of Pharmacy recently fined Florida-based Brooksville Pharmaceuticals $250,000 for shipping 153 prescriptions of the investigational GLP-1 drug retatrutide into the state.
• Misleading Marketing Warnings: According to a July 15 report, the FDA has now sent warning letters to over 80 compounders and telehealth companies—including a coordinated action against 30 telehealth firms in 2026 alone—for misleading advertising. Regulators flagged websites for failing to disclose that compounded products are not FDA-approved and for heavily implying equivalence to brand-name drugs.

Market Watch

Telehealth Operators Feel the Squeeze from Pharma Litigation

The commercial landscape for compounded weight-loss drugs remains treacherous as Eli Lilly and Novo Nordisk maintain aggressive litigation campaigns against unauthorized compounders and telehealth prescribers. Novo Nordisk's previous patent infringement lawsuit against telehealth giant Hims & Hers ultimately forced Hims to abandon its compounded GLP-1 offerings in favor of branded Wegovy. The pivot proved costly; reports this week highlight Hims taking a $92 million Q1 loss alongside a $33 million write-down on compounding supply chain materials. Furthermore, an SEC inquiry into the company's compounding practices remains open.

Meanwhile, the compounding industry continues to wait for the FDA to finalize its April 2026 proposal to permanently exclude semaglutide and tirzepatide from the "503B Bulks List," which would effectively close the legal pathway for large-scale outsourcing facilities to manufacture the drugs.

Compliance Takeaway for RP Wellness

This week's news underscores an incredibly volatile regulatory environment for peptide suppliers. With the FDA aggressively pursuing unapproved API distributors and issuing warning letters for misleading claims, research-use-only (RUO) suppliers must rigorously enforce their compliance guardrails. Ensure that all products are strictly labeled and marketed for research purposes only, not for human consumption, and avoid any marketing language that implies clinical safety, efficacy, or equivalence to FDA-approved therapies. The outcome of the July 23-24 PCAC meeting will likely set a new regulatory precedent for high-demand peptides like BPC-157 and TB-500.